A Phase Ib Clinical Trial to Optimize Risk Benefit of REGN5678 (PSMAxCD28 Bispecific Antibody) Plus Cemiplimab (Anti-PD-1 Monoclonal Antibody) in Patients With Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 08 Oct 2025
At a glance
- Drugs Nezastomig (Primary) ; Cemiplimab
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
Most Recent Events
- 11 Sep 2025 Status changed from not yet recruiting to recruiting.
- 18 Feb 2025 New trial record